-+ 0.00%
-+ 0.00%
-+ 0.00%

Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer

PUBT·06/23/2026 12:02:51
Listen to the news
Revolution Medicines starts Phase 3 RASolute 305 trial of zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic cancer
  • Revolution Medicines began treating patients in RASolute 305, a global Phase 3 trial of zoldonrasib with chemotherapy in first-line metastatic RAS G12D pancreatic cancer.
  • No new trial results were presented; the study will read out progression-free survival and overall survival outcomes in the future.
  • The trial tests whether adding zoldonrasib can improve disease control and survival versus chemotherapy alone, with safety and patient-reported outcomes tracked.
  • The start follows earlier daraxonrasib data reported in second-line metastatic pancreatic cancer that showed improved outcomes versus standard chemotherapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230800PRIMZONEFULLFEED9750882) on June 23, 2026, and is solely responsible for the information contained therein.